HAVCR2 and vulva cancer: The expression of TIM-3 and its ligand, Galectin-9, has been identified in various malignancies, including cervical and vulvar cancers, indicating a potential role for TIM-3 checkpoint inhibition in combination with anti-PD-1/PD-L1 therapies (61).